Vancouver-based healthtech company Light AI is broadening the scope of its upcoming wellness platform, adding the ability to rule out COVID-19 and conjunctivitis (pink eye), alongside its original focus on Strep A.
The direct-to-consumer platform, expected to launch in the third quarter of 2025, uses artificial intelligence to help individuals and families quickly detect and manage common health conditions.
Light AI says the expansion enhances its addressable market and creates new opportunities for licensing and partnerships, positioning the platform as a foundational tool in its growing suite of diagnostic solutions.
“Timely diagnosis is known to drive better health outcomes, yet nearly 50% of the global population lacks access to basic diagnostics, exposing a massive gap in care and a high-growth market ripe for innovation,” said Peter Whitehead, CEO of Light AI.
Light AI is a member of the BC Tech Association.
BC Tech is the largest member-led technology non-profit in British Columbia, and we’re dedicated to turning startups and scaleups into the anchor companies of tomorrow. Our work supports members to grow and diversify their talent pool, acquire new customers, access capital and accelerate their scaleup journey. Technology is a key industry for BC’s future and builds resiliency in every industry. Today, every company is a tech company. Join now.
“For these reasons, we are thrilled to introduce our comprehensive wellness platform, which will empower families and individuals to manage common yet impactful health issues more effectively.”
Light AI’s algorithm for Strep A—a potentially serious infection if left untreated—relies on machine learning to support accurate and timely diagnosis. The company expects this feature to drive adoption of the platform and future offerings.
In response to the ongoing burden of COVID-19, especially in high-risk environments like long-term care facilities, the platform will include tools to support early identification and containment.
Light AI’s pink eye algorithm, meanwhile, has achieved 99% accuracy in ruling out the condition, which affects roughly 6 million people annually in the U.S. alone and can lead to serious complications if unmanaged.
The company notes that these expanded capabilities will contribute to a scalable diagnostic ecosystem, with user-generated data feeding into future predictive models.
Leave a Reply